Bangalore, India -- (SBWIRE) -- 11/29/2016 -- Diabetic Retinopathy – Pipeline Review, H2 2016, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.
Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.
Diabetic Retinopathy – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 5, 1, 33, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.Diabetic Retinopathy.
Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Spanning over 237 pages "Diabetic Retinopathy - Pipeline Review, H2 2016" report covers Report Coverage, Diabetic Retinopathy Overview, Therapeutics Development, Clinical Stage Products, Appendix. This report Covered Companies - Acucela Inc., Aerie Pharmaceuticals, Inc., Aerpio Therapeutics, Inc., Amakem NV, Antisense Therapeutics Limited, Araim Pharmaceuticals, Inc., BCN Peptides, S.A., Biomar Microbial Technologies, Charlesson LLC., Coherus BioSciences, Inc., Crinetics Pharmaceuticals, Inc., Diffusion Pharmaceuticals Inc, Dimerix Bioscience Pty Ltd, Dynamis Therapeutics, Inc., EyeGene Inc, Foresee Pharmaceuticals, LLC, Formycon AG, Icon Bioscience, Inc., Islet Sciences, Inc., Kodiak Sciences Inc., Kowa Company, Ltd., LegoChem Biosciences, Inc, Lpath, Inc., M's Science Corporation, Mabion SA, MingSight Pharmaceuticals, OcuCure Therapeutics, Inc., Oculis ehf, Ohr Pharmaceutical Inc., PanOptica, Inc., Profarma, Promedior, Inc., Regeneron Pharmaceuticals Inc, Retrotope, Inc, Ribomic Inc., Stelic Institute & Co., Inc., Stemedica Cell Technologies, Inc., Strongbridge Biopharma plc, Sucampo Pharmaceuticals, Inc., Targazyme, Inc., ThromboGenics NV, TWi Pharmaceuticals, Inc., VESSL Therapeutics Ltd.
For more information Visit at: http://www.drugpipeline.net/global-markets-direct/diabetic-retinopathy-pipeline-review-h2-2016
Muscular Dystrophy - Pipeline Review, H2 2016 - Visit at - http://www.drugpipeline.net/global-markets-direct/muscular-dystrophy-pipeline-review-h2-2016
Pemphigus Vulgaris - Pipeline Review, H2 2016 - Visit at - http://www.drugpipeline.net/global-markets-direct/pemphigus-vulgaris-pipeline-review-h2-2016
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.